Provided is a compound represented by formula (1). In formula (1), Ar.sup.1, Ar.sup.2, and Ar.sup.3 represent a 1,4-phenylene group or a divalent sulfur-containing aromatic heterocyclic group optionally having a substituent, and at least one of Ar.sup.1 and Ar.sup.2 has a fluorine atom as a substituent; n represents 1 or 2; R.sup.1 represents a single bond or a group selected from the group consisting of —OC(═O)—, —C(═O)O—, —C≡C—, —CH═CH—, —CH═N—, and —N═CH—; R.sup.2 represents an alkylamino group or an alkoxy group; R.sup.3 represents a group selected from the group consisting of an alkanediyl group, an alkanediyloxy group, an alkanediyloxycarbonyl group, and an alkanediylcarbonyloxy group; and R.sup.4 represents a polymerizable group or a hydrogen atom.

R.sup.4—R.sup.3-Ar.sup.1-(-R.sup.1-Ar.sup.2-).sub.n-N═N-Ar.sup.3-R.sup.2  (1)

Provided is a compound represented by formula (1). In formula (1), Ar.sup.1, Ar.sup.2, and Ar.sup.3 represent a 1,4-phenylene group or a divalent sulfur-containing aromatic heterocyclic group optionally having a substituent, and at least one of Ar.sup.1 and Ar.sup.2 has a fluorine atom as a substituent; n represents 1 or 2; R.sup.1 represents a single bond or a group selected from the group consisting of —OC(═O)—, —C(═O)O—, —C≡C—, —CH═CH—, —CH═N—, and —N═CH—; R.sup.2 represents an alkylamino group or an alkoxy group; R.sup.3 represents a group selected from the group consisting of an alkanediyl group, an alkanediyloxy group, an alkanediyloxycarbonyl group, and an alkanediylcarbonyloxy group; and R.sup.4 represents a polymerizable group or a hydrogen atom.

R.sup.4—R.sup.3-Ar.sup.1-(-R.sup.1-Ar.sup.2-).sub.n-N═N-Ar.sup.3-R.sup.2  (1)

A fluorine-containing substituted benzothiophene compound and a pharmaceutical composition and an application thereof are described. The compound has the structure as shown in formula (I), in which the definitions of each group and substituent are as described in the description. A preparation method of the compound and an anti-tumor application thereof are also described.

##STR00001##

The present invention relates to compound of Formula (I)

##STR00001##

containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.

The present invention relates to compound of Formula (I)

##STR00001##

containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.

The present invention relates to compound of Formula (I) containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor. ##STR00001##

The present invention relates to compound of Formula (I) containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor. ##STR00001##

Compounds of formula (I), wherein R.sub.1 is as defined in the claims, exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors. Methods of treatment and pharmaceutical dosage forms are also disclosed.

Compounds of formula (I), wherein R.sub.1 is as defined in the claims, exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors. Methods of treatment and pharmaceutical dosage forms are also disclosed.

The present invention relates to a method for the metal-free preparation of a biaryl compound by a photosplicing reaction and its use in the preparation of chemical compounds, preferably of active ingredients e.g. in the fields of pharmaceuticals and agrochemicals. In particular, it refers to a method for the regiocontrolled preparation of a biaryl compound of formula (I): ArAr by photochemically reacting a precursor compound of formula (II): ArLAr to form a biaryl compound of general formula: ArLAr(II).fwdarw.ArAr (I) wherein Ar and Ar, independently of each other, represent an unsubstituted or substituted C6-C20 aryl group or a heteroaryl group with 5-20 ring atoms selected from carbon, nitrogen, oxygen and sulfur, and L represents a group XYZ as defined herein. The biaryl compounds are generally suitable as intermediates or key building blocks in a very broad spectrum of organic chemical syntheses and their respective utilities. Their use within the field of synthesis of active ingredients is an aspect of the invention, and their use in the preparation of pharmaceutically active ingredients is particularly preferred.